This paper is in the following e-collection/theme issue:

Mass Media/Social Media Communication and Campaigns (446) Medicine 2.0: Social Media, Open, Participatory, Collaborative Medicine (1552) Infodemiology and Infoveillance (1269) Adverse Drug Events Detection, Pharmacovigilance and Surveillance (143) Safety and Error Prevention in Health (186) Infoveillance, Infodemiology, Digital Disease Surveillance, Infodemic Management (1010)

Published on in Vol 4, No 1 (2018): Jan-Mar

Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis

Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis

Social Media Impact of the Food and Drug Administration's Drug Safety Communication Messaging About Zolpidem: Mixed-Methods Analysis

Authors of this article:

Michael S Sinha1 Author Orcid Image ;   Clark C Freifeld2 Author Orcid Image ;   John S Brownstein3 Author Orcid Image ;   Macarius M Donneyong4 Author Orcid Image ;   Paula Rausch5 Author Orcid Image ;   Brian M Lappin5 Author Orcid Image ;   Esther H Zhou5 Author Orcid Image ;   Gerald J Dal Pan5 Author Orcid Image ;   Ajinkya M Pawar1 Author Orcid Image ;   Thomas J Hwang1 Author Orcid Image ;   Jerry Avorn1 Author Orcid Image ;   Aaron S Kesselheim1 Author Orcid Image
Article Authors Cited by (22) Tweetations (55) Metrics

Journals

  1. Lang S, Böhringer D, Bach M, Reinhard T. Analysis of user behavior on the website of a university eye hospital in Germany. Medicine 2020;99(30):e21348 View
  2. . Impact of social media on the US FDA alerts for zolpidem. Reactions Weekly 2018;1685(1):6 View
  3. Mazhar H, Foster B, Necyk C, Gardiner P, Harris C, Robaey P. Natural Health Product–Drug Interaction Causality Assessment in Pediatric Adverse Event Reports Associated with Attention-Deficit/Hyperactivity Disorder Medication. Journal of Child and Adolescent Psychopharmacology 2020;30(1):38 View
  4. Fabbri A, O'Keeffe M, Moynihan R, Møllebæk M, Mohammad A, Bhasale A, Puil L, Mintzes B. Media coverage of drug regulatory agencies' safety advisories: A case study of citalopram and denosumab. British Journal of Clinical Pharmacology 2020;86(7):1416 View
  5. Borchert J, Wang B, Ramzanali M, Stein A, Malaiyandi L, Dineley K. Adverse Events Due to Insomnia Drugs Reported in a Regulatory Database and Online Patient Reviews: Comparative Study. Journal of Medical Internet Research 2019;21(11):e13371 View
  6. de Vries E, Denig P, de Vries S, Monster T, Hugtenburg J, Mol P. Drug Safety Issues Covered by Lay Media: A Cohort Study of Direct Healthcare Provider Communications Sent between 2001 and 2015 in The Netherlands. Drug Safety 2020;43(7):677 View
  7. . RETRACTED ARTICLE: Digital Ethnography of Zoophilia — A Multinational Mixed-Methods Study. Journal of Sex & Marital Therapy 2019;45(1):1 View
  8. Pappa D, Stergioulas L. Harnessing social media data for pharmacovigilance: a review of current state of the art, challenges and future directions. International Journal of Data Science and Analytics 2019;8(2):113 View
  9. Kesselheim A, Sinha M, Campbell E, Schneeweiss S, Rausch P, Lappin B, Zhou E, Avorn J, Dal Pan G. Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. Drug Safety 2019;42(11):1287 View
  10. Geller A, Zhou E, Budnitz D, Lovegrove M, Dal Pan G. Changes in emergency department visits for zolpidem‐attributed adverse drug reactions after FDA Drug Safety Communications. Pharmacoepidemiology and Drug Safety 2020;29(3):352 View
  11. Lim S, Bolster M. Challenges in Optimizing Medical Education for Rheumatologists. Rheumatic Disease Clinics of North America 2019;45(1):127 View
  12. Kesselheim A, Sinha M, Rausch P, Lu Z, Tessema F, Lappin B, Zhou E, Dal Pan G, Zwanziger L, Ramanadham A, Loughlin A, Enger C, Avorn J, Campbell E. Patients' Knowledge of Key Messaging in Drug Safety Communications for Zolpidem and Eszopiclone: A National Survey. The Journal of Law, Medicine & Ethics 2019;47(3):430 View
  13. Gachloo M, Wang Y, Xia J. A review of drug knowledge discovery using BioNLP and tensor or matrix decomposition. Genomics & Informatics 2019;17(2):e18 View
  14. Schiro J, Shan L, Tatlow-Golden M, Li C, Wall P. #Healthy: smart digital food safety and nutrition communication strategies—a critical commentary. npj Science of Food 2020;4(1) View
  15. Kajetanowicz A, Kajetanowicz A. PROS AND CONS OF TECHNOLOGY FOR PATIENTS. Wiadomości Lekarskie 2019;72(6):1178 View
  16. Radawski C, Hammad T, Colilla S, Coplan P, Hornbuckle K, Freeman E, Smith M, Sobel R, Bahri P, Arias A, Bennett D. The utility of real‐world evidence for benefit‐risk assessment, communication, and evaluation of pharmaceuticals: Case studies. Pharmacoepidemiology and Drug Safety 2020;29(12):1532 View
  17. Dal Pan G. The Use of Real‐World Data to Assess the Impact of Safety‐Related Regulatory Interventions. Clinical Pharmacology & Therapeutics 2022;111(1):98 View
  18. Coca J, Coca-Asensio R, Esteban Bueno G. Socio-historical analysis of the social importance of pharmacovigilance. Frontiers in Sociology 2022;7 View
  19. Bahri P, Bowring G, Edwards B, Anton C, Aronson J, Caro-Rojas A, Hugman B, Mol P, Trifirò G, Ilic K, Daghfous R, Fermont I, Furlan G, Gaissmaier W, Geer M, Hartigan-Go K, Houÿez F, Neth H, Norgela G, Oppamayun Y, Raynor D, Bouhlel M, Santoro F, Sultana J. Communicating for the Safe Use of Medicines: Progress and Directions for the 2020s Promoted by the Special Interest Group of the International Society of Pharmacovigilance. Drug Safety 2023;46(6):517 View
  20. Litvinova O, Matin F, Matin M, Zima-Kulisiewicz B, Tomasik C, Siddiquea B, Stoyanov J, Atanasov A, Willschke H. Patient safety discourse in a pandemic: a Twitter hashtag analysis study on #PatientSafety. Frontiers in Public Health 2023;11 View
  21. Leiter V. Signs and symptoms: Adverse events associated with a sterilization device. Social Science & Medicine 2024;351:116963 View

Books/Policy Documents

  1. Bahri P. Communicating about Risks and Safe Use of Medicines. View